Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04611113

Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer

Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2025-05-01

86

Participants Needed

1

Research Sites

295 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of the present project is to evaluate in a randomised, controlled, open-label, two parallel treatment groups pilot study, the efficacy of oral nutritional supplementation with a high-protein-high calorie mixture containing immunonutrients compared to a standard high-calorie-high-protein nutritional blend, in addition to nutritional counseling, in improving tolerance to chemoradiotherapy (CT-RT) in patients with tumours of the head and neck

CONDITIONS

Official Title

Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of head-neck cancer
  • Planned curative or adjuvant chemoradiotherapy
  • Willingness to participate in planned measurements and provide written informed consent
Not Eligible

You will not qualify if you...

  • Younger than 18 years
  • Currently receiving or planned for artificial nutrition
  • Refusal to participate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy, 27100

Actively Recruiting

Loading map...

Research Team

R

Riccardo Caccialanza, MD

CONTACT

E

Emanuele Cereda, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here